Pathophysiology and treatment of hepatitis C

Drugs

Volumn 52, Issue SUPPL. 2, 1996, Pages 1-8

  Thomas, H C ^a,b   Booth, J ^a   Brown, J ^a  

^a IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

^b ST MARY S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTIPYRETIC AGENT; RIBAVIRIN; URSODEOXYCHOLIC ACID;

BONE MARROW DEPRESSION; CLINICAL TRIAL; CONFERENCE PAPER; DEPRESSION; DISEASE COURSE; FEVER; GASTROINTESTINAL SYMPTOM; HAIR LOSS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER FIBROSIS; ORAL DRUG ADMINISTRATION; PATHOPHYSIOLOGY; PATIENT CARE; PHLEBOTOMY; RELAPSE; THROMBOCYTOPENIA;

HEPATITIS C VIRUS;

EID: 0029824574     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-199600522-00003     Document Type: Conference Paper

References (53)

1. Linnen J, Wages J, Zhang-Keck ZY, et al. Molecular cloning and disease association of hepatitis G virus: a new transfusion transmissible agent. Science 1996. In press
2. Mutimer D, Harrison R, O'Donnell K, et al. Hepatitis C virus infection in the asymptomatic British blood donor. J Viral Hepatitis 1995; 2: 47-53
3. Esteban J, Viladomiu L, Gonzalez A, et al. Hepatitis C virus antibodies among risk groups in Spain. Lancet 1989; 334: 294-7
4. Delaporte E, Thiers V, Dazza M, et al. High level of hepatitis C endemicity in Gabon, equatorial Africa. Trans R Soc Trop Med 1993; 87: 636-7
5. Saeed A, Al-Admawi A, Al-Rasheed A, et al. Hepatitis C virus infection in Egyptian volunteer blood donors in Riyadh. Lancet 1991; 338: 459-60
6. Alter MJ, Margolis HS, Krawczynski K, et al. The natural history of community-acquired hepatitis C in the United States. N Engl J Med 1992; 327 (27): 1899-905
7. Alberti A, Morsica G, Chemello L, et al. Hepatitis C viraemia and liver disease in symptom-free individuals with anti-HCV. Lancet 1992; 340: 647-8
8. Seeff LB, Buskell-Bales Z, Wright EC, et al. Long-term mortality after transfusion-associated non-A, non-B hepatitis. N Engl J Med 1992; 327 (27): 1906-11
9. Tremolada F, Casarin C, Alberti A, et al. Long-term follow-up of non-A, non-B (type C) post-transfusion hepatitis. J Hepatol 1992; 16(3): 273-81
10. Yuki N, Hayashi N, Kamada T. HCV viraemia and liver injury in symptom-free blood donors. Lancet 1993; 342: 444
11. Pozzato G, Moretti M, Franzin F, et al. Severity of liver disease with different HCV clones. Lancet 1991; 338: 509
12. Honda M, Kaneko S, Sakai A, et al. Degree of diversity of hepatitis C virus quasispecies and progression of liver disease. Hepatology 1994; 20 (5): 1144-51
13. Gordon S, Elloway R, Long J, et al. The pathology of hepatitis C as a function of mode of transmission: blood transfusion vs intravenous drug use. Hepatol 1993; 18 (6): 1338-43
14. Lau JYN, Davis GL, Kniffen J, et al. Significance of serum hepatitis C virus RNA levels in chronic hepatitis C. Lancet 1993; 341: 1501-4
15. Bjoro K, Froland S, Yun Z, et al. Hepatitis C infection in patients with primary hypogammaglobulinaemia after treatment with contaminated immune globulin. NEJM 1994; 331: 1607-11
16. Nalpas B, Thiers V, Pol S, et al. Hepatitis C viremia and anti-HCV antibodies in alcoholics. J Hepatol 1992; 14: 381-4
17. Takase S, Tsutsumi M, Kawahara H, et al. The alcohol-altered liver membrane antibody and hepatitis C virus infection in the progression of alcoholic liver disease. Hepatology 1993; 17: 9-13
18. Weltman M, Brotodihardjo A, Crewe E, et al. Coinfection with hepatitis B and C, C and D viruses results in severe chronic liver disease and responds poorly to interferon-α treatment. J Viral Hepatitis 1995; 2: 39-45
19. Martin P, Di Bisceglie AM, Kassianides C, et al. Rapidly progressive non-A, non-B hepatitis in patients with human immunodeficiency virus infection. Gastroenterology 1989; 97: 1559-61
20. Simmonds P, Rose KA, Graham S, et al. Mapping of serotype-specific, immunodominant epitopes in the NS-4 region of hepatitis C virus (HCV): use of type-specific peptides to serologically differentiate infections with HCV types 1, 2 and 3. J Clin Microbiol 1993; 31 (6): 1493-503
21. Bukh J, Purcell R, Miller R. At least 12 genotypes of hepatitis C virus predicted by sequence analysis of the putative EI gene of isolates collected worldwide. P.N.A.S 1993; 90: 8234-8
22. Simmonds P, Smith DB, McOmish F, et al. Identification of genotypes of hepatitis C virus by sequence comparisons in the core. E1 and NS-5 regions. J Gen Virol 1994; 75: 1053-61
23. Okamoto H, Sugiyama Y, Okada S, et al. Typing hepatitis C virus by polymerase chain reaction with typespecific primers: applicalion to clinical surveys and tracing infectious sources. J Gen Virol 1992; 73: 673-9
24. McOmish F, Chan S-W, Dow BC, et al. Detection of three types of hepatitis C virus in blood donors: investigation of type-specific differences in serologic reactivity and rate of alanine aminotransferase abnormalities. Transfusion 1993; 33 (1): 7-13
25. Stuyver L, Rossau R, Wyseur A, et al. Typing of hepatitis C virus isolates and characterization of new subtypes using a line probe assay. J Gen Virol 1993; 74: 1093-102
26. Dusheiko G, Schmilovitz-Weiss H, Brown D, et al. Hepatitis C virus genotypes: an investigation of type-specific differences in geographic origin and disease. Hepatol 1944; 19 (1): 13-8
27. Booth J, Foster G, Kumar U, et al. Chronic hepatitis C virus infections: predictive value of genotype and level of viraemia on disease progression and response to interferon α. Gut 1995; 36: 427-32
28. Kanai K, Kako M, Okamoto H. HCV genotypes in chronic hepatitis C and response to interferon. Lancet 1992; 339: 1543
29. Tsubota A, Chayama K, Ikeda K, et al. Factors predictive of response to interferon-α therapy in hepatitis C virus infection. Hepatology 1994; 19 (5): 1088-94
30. Causse X, Godinot H, Chevallier M, et al. Comparison of 1 or 3 MU of interferon alfa-2b and placebo in patients with chronic non-A, non-B hepatitis. Gastroenterol 1991; 101 (2): 497-502
31. Jouet P, Roudot-Thoraval F, Dhumeaux D, et al. Comparative efficacy of interteron alpha in cirrhotic and non-cirrhotic patients with non-A non-B hepatitis. Gastroenterology 1994; 106: 686-90
32. Gomez-Rubio M, Porres J, Castillo I, et al. Prolonged treatment (18 months) of chronic hepatitis C with recombinant alpha-interferon in comparison with a control group. J Hepatol 1990; 11 Suppl. 1: S63-7
33. Saracco G, Rosina F, Torrani, et al. A randomized controlled trial of interferon alfa-2b as therapy for chronic non-A, non-B hepatitis. J Hepatol 1990; 11 Suppl. 1: S43-9
34. Realdi G, Diodati G, Bonetti P, et al. Recombinant human interferon-alfa-2a in community-acquired non-A, non-B chronic active hepatitis: preliminary results of a randomized, controlled trial. J Hepatol 1990; 11 Suppl. 1: 68-71
35. Jacyna MR, Brooks MG, Loke RH, et al. Randomised controlled trial of interferon alpha (lymphoblastoid interferon) in chronic non-A non-B hepatitis. BMJ 1989; 298: 80-2
36. Davis GL, Balart LA. Schiff ER, et al. Treatment of chronic hepatitis C with recombinant interferon alfa: a multicenter, randomized, controlled trial. N Engl J Med 1989; 321: 1501-6
37. Weilland O, Wejstal R, Norkrans G, et al. A randomised open study of interferon alpha -2b treatment of chronic non-A, non-B post-transfusion hepatitis: no correlation of outcome to presence of hepatitis C virus antibodies. Scand J Infect Dis 1989; 21 (6): 617-25
38. Budillon G, Cimino L, Del Vecchio Blanco C, et al. Long-term follow-up evaluation in HCV chronic hepatitis treated with alfa-2B interferon: a comparison of two protocols. Ital J Gastroenterol 1994; 26: 16-20
39. Dibisceglie AM, Martin P, Kassianides C, et al. A randomized, double-blind, placebo-controlled trial of recombinant human alpha-interferon therapy for chronic non-A, non-B (type-C) hepatitis. J Hepatol 1990; 11 Suppl. 1: 36-42
40. Iino S, Hino K, Kuroki T, et al. Treatment of chrome hepatitis C with high dose interferon alpha-2b. A multicenter study. Dig Dis Sci 1993; 38 (4): 612-8
41. Kasahara A, Hayashi N, Hiramatsu N, et al. Ability of prolonged Interferon treatmenl to suppress relapse after cessation of therapy in patients with chronic hepatitis C: a multicenter randomised controlled trial. Hepatology 1995; 21 (2): 291-7
42. Booth JCL, Brown JL, Thomas HC. The management of chronic HCV infection. Gut 1995; 37: 449-54
43. Reichard O, Andersson J, Schvarez R, et al. Ribavirin treatment for chronic hepatitis C. Lancet 1991; 337: 1058-61
44. Di Bisceglie A, Shindo M, Fong T-L, et al. A pilot study of ribavirin therapy for chronic hepatitis C. Hepatology 1994; 16: 649-54
45. Dusheiko G, Weiland O, Thomas H, et al. Results of a placebo-controlled study of ribavirin in patients with chronic hepatitis C [abstract 440]. Hepatology 1994; 20 (4) [Pt 2]: 206
46. Brillanti S, Garson J, Foli M, et al. A pilot study of combination therapy with ribavirin plus interferon alfa for interferon alfa-resistant chronic hepatitis C. Gastroenterology 1994; 107: 812-7
47. Chemello L, Cavalletto L, Bernardinelli E, et al. Response to ribavirin, to interferon and to a combination of both in patients with chronic hepatitis C and its relation to HCV genotype [abstract]. J Hepatol 1994; 21 Suppl. 1: S12
48. Van Thiel D, Friedlander L, Fagiuoli S, et al. Response to interferon α therapy is influenced by the iron content of the liver. J Hepatol 1994; 20: 410-5
49. Olynyk J, Reddy R, Di Bisceglie A, et al. Hepatic iron concentration as a predictor of response to interferon alpha therapy in chronic hepatitis C. Gastroenterology 1995; 108: 1104-9
50. Careni P, Fagiuoli S, Van Thiel D. Iron reduction therapy: simply camouflage, or a real weapon? Am J Gastroenterol 1995; 89 (7): 970-3
51. Hayashi H, Takikawa T, Nishimura N, et al. Improvement of serum aminotransferase levels after phlebotomy in patients with chronic active hepatitis C and excess hepatic iron. Am J Gastroenterol 1994; 89: 986-8
52. Bellentani S, Podda M, Tiribelli C, et al. Ursodiol in the long-term treatment of chronic hepatitis: a double-blind multicenter clinical trial. J Hepatol 1993; 19 (3): 459-64
53. Boucher F, Jouanolle H, Andre P, et al. Interferon and ursodeoxycholic acid combined therapy in the treatment of chronic viral C hepatitis: results from a controlled randomised trial in 80 patients. Hepatology 1995; 21 (2): 322-7